ISPOR CEO Nancy Berg Named a PharmaVOICE 100
Annual List Recognizes Inspirational Individuals Who Have Made Positive Contributions to the Life Sciences Industry
Article ID: 658689
Released: 8-Aug-2016 8:05 AM EDT
Newswise — Princeton, NJ—August 8, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced that its Chief Executive Officer Nancy Berg has been named a 2016 PharmaVOICE 100.
The PharmaVOICE 100 was established twelve years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life sciences industry. The PharmaVOICE 100 honorees represent a broad cross-section of the global life-sciences industry, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, advertising, digital, marketing, technology, academia, and many other sectors. This diverse group of individuals also represents a wide variety of functional areas ranging from the clinic to the C-suite.
Berg assumed the role of CEO and Executive Director of ISPOR, a non-profit organization based in central New Jersey, in 2014. Over the past 20 years, ISPOR has become a the leading global scientific and educational organization for health economics and outcomes research (HEOR). PharmaVOICE highlights Berg’s forward-thinking and strategic leadership as a key to positioning ISPOR as a global leader in HEOR.
"This must-read issue has become one of the most-anticipated and highly regarded publications of the year, and it is our great pleasure to showcase the 100 men and women who are demonstrating inspired leadership, innovating across the ecosystem, creating transformative change, disrupting the status quo, and building relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients," said Taren Grom, Editor and Co-founder of PharmaVOICE.“I am deeply honored to be among the PharmaVOICE 100 leaders recognized this year,” noted Berg. “ISPOR’s members play an essential role in improving health care by bringing research excellence into the everyday health decisions that impact patients’ lives. It is a true honor to serve the Society at a time when the importance of HEOR has never been greater.”
ABOUT ISPORThe International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that promotes health economics and outcomes research excellence to improve decision making for health globally. Web: www.ISPOR.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT |Facebook: http://bit.ly/ISPOR-FB
About PharmaVOICEPublished monthly, with the combined July/August PharmaVOICE 100 and November/December Year in Preview issues, PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of the executives who are shaping the direction of the dynamic and multifaceted life-sciences industry. PharmaVOICE reaches more than 41,000 BPA qualified subscribers and 100,000 users with its digital edition. PharmaVOICE's unique horizontal editorial approach cuts across industry silos, providing a holistic overview of the life-sciences industry, addressing a range of topics from molecule through market. By engaging compelling personalities from diverse industry sectors, PharmaVOICE provides multiple perspectives on business challenges, trends, and topics. Editorial content sparks dialog, initiates debate, and opens the lines of communication to facilitate and improve business-to-business relationships. PharmaVOICE's multiple-perspective and in-depth original forums, feature articles, topics, and departments are audience-driven. PharmaVOICE provides executives with useful peer-to-peer insights on a broad range of business practices and topics to a wide range of life-science sectors.